LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compounds Detected in Breath Samples Specific to Ovarian Cancer

By LabMedica International staff writers
Posted on 13 Oct 2015
Image: Schematic representation of analysis of breath samples for the diagnosis of ovarian cancer (Photo courtesy of Technion).
Image: Schematic representation of analysis of breath samples for the diagnosis of ovarian cancer (Photo courtesy of Technion).
Diagnosing cancer today usually involves various imaging techniques, examining tissue samples under a microscope, or testing cells for proteins or genetic material.

In search of safer and less invasive ways to tell if someone has cancer, analyzing breath and defining specific profiles of compounds in breath samples is under investigation, but translating these exhaled disease fingerprints into a meaningful diagnosis has required a large number of sensors, which makes them impractical for clinical use.

Chemical engineers at the Technion, Israel Institute of Technology (Haifa, Israel) and their colleagues developed a small, breath-diagnostic array based on flexible gold-nanoparticle sensors for use in an “electronic nose.” Flexible sensors based on molecularly modified gold nanoparticles (GNPs) were integrated into a dynamic cross-reactive diagnostic sensing array. Each bending state of the GNP-based flexible sensor gives unique nanoparticle spatial organization, altering the interaction between GNP ligands and volatile organic compounds (VOCs), which increases the amount of data obtainable from each sensor.

Individual dynamic flexible sensor could selectively detect parts per billion (ppb) level VOCs that are linked with ovarian cancers in exhaled breath and discriminate them from environmental VOCs that exist in exhaled breath samples, but do not relate to ovarian cancer per se. Strain-related response successfully discriminated between exhaled breath collected from 43 volunteers, 17 of whom had ovarian cancer, with data from a single sensor being sufficient to obtain 82% accuracy, on breath samples irrespective of important confounding factors, such as tobacco consumption and comorbidities. The approach raises the hope of achieving an extremely simple, inexpensive, portable, and noninvasive diagnostic procedure for cancer and other diseases. The study was published online on September 9, 2015, in the journal Nano Letters.

Related Links:

Technion, Israel Institute of Technology


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more